Xilio Therapeutics Highlights Advancements in Cancer Treatment Trials
Xilio Therapeutics, Inc. (Nasdaq: XLO), a pioneering clinical-stage biotechnology company, is making significant strides in the development of tumor-activated immuno-oncology therapies aimed at improving outcomes for cancer patients. Recently, the company announced exciting plans to share initial data from its ongoing Phase 2 trial involving vilastobart (XTX101), a tumor-activated, high-affinity binding anti-CTLA-4 antibody. This presentation is set to take place at the prestigious ASCO Gastrointestinal (ASCO GI) Cancers Symposium.
Initial Findings from Vilastobart Trial
Scheduled for the ASCO GI event, Xilio will reveal findings related to the combination of vilastobart and atezolizumab (Tecentriq) specifically for patients suffering from metastatic microsatellite stable colorectal cancer (MSS CRC). The preliminary data collected from the earlier Phase 1C dosage escalation trials has already shown promise, indicating encouraging responses in patients with cold tumors, including MSS colorectal cancer.
Quote from Xilio's Chief Medical Officer
Dr. Katarina Luptakova, the Chief Medical Officer at Xilio, expressed her optimism regarding the trial results. "The initial responses we've observed in patients undergoing treatment with vilastobart and atezolizumab during our Phase 1 trials are quite promising. We can't wait to present the comprehensive data at ASCO GI,” she noted. Moreover, the excitement surrounding the preliminary Phase 1 data for XTX301, an investigational tumor-activated IL-12, adds to the anticipation of future advancements in cancer therapy.
Details of the ASCO GI Presentation
Xilio's ASCO GI presentation will outline the combination therapy's initial data from the ongoing Phase 2 trial. The specifics of the presentation are:
- Title: Phase 1/2 study of XTX101 in combination with atezolizumab for advanced solid tumors and MSS CRC
- Abstract Number: 206
- Presentation Date: January 25, 2025
- Poster Session C: Cancers of the Colon, Rectum, and Anus
- Time: 7:00 AM-7:55 AM PST
- Location: Moscone West, San Francisco, CA
Insights from Preliminary Phase 1 Data for XTX301
The company has observed significant progress in the clinical trial for XTX301, a novel tumor-activated IL-12. Preliminary findings show that XTX301 has the potential to enhance anti-tumor immunity without dose-limiting toxicities, a common concern in cancer therapies. Particularly noteworthy is the clinical profile of XTX301, which has demonstrated sustained interferon gamma signaling without the unpleasant effects typically associated with similar agents.
Patient Treatment Details
As of a recent data assessment, 34 patients with advanced solid tumors received XTX301 dosages ranging from 5 µg/kg to 60 µg/kg, administered every three weeks or six weeks. Most participants had undergone three or more prior lines of anti-cancer therapy, indicating the need for innovative solutions in heavily pre-treated patients.
Financial Developments with Gilead
Xilio also confirmed a significant financial boost through a recent private placement with Gilead Sciences, incurring an aggregate of approximately $8.2 million. This transaction is part of a series of financial engagements initiated in 2024, securing nearly $25 million. These funds are expected to sustain operational expenses and capital requirements well into late 2025, a reassuring signal for continued research and development efforts.
Understanding Vilastobart and XTX301
Vilastobart represents an innovative approach as a tumor-activated, Fc-enhanced monoclonal antibody. It acts by blocking CTLA-4 and selectively disrupting regulatory T cell functions within the tumor microenvironment. The collaborative efforts with Roche to evaluate vilastobart alongside atezolizumab have the potential to revolutionize treatments for conditions resistant to existing therapies.
Exploring XTX301
XTX301 is designed to invigorate the immune response and reprogram the tumor microenvironment of cancer patients with poorly immunogenic tumors. An exclusive license agreement with Gilead has propelled this program forward, ensuring that it remains at the forefront of immuno-oncology research.
About Xilio Therapeutics
As an innovative company committed to enhancing cancer treatments, Xilio Therapeutics is focused on developing tumor-activated immuno-oncology therapies that aim to minimize systemic side effects while maximizing therapeutic efficacy. Their unique platform continues to advance the discovery of new therapeutic avenues, consisting of cytokines, antibodies, bispecifics, and immune cell engagers dedicated to improving patient outcomes.
Frequently Asked Questions
What is XTX101?
XTX101, also known as vilastobart, is a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody designed to block CTLA-4 in the tumor microenvironment.
What was recently announced by Xilio Therapeutics?
Xilio announced initial data from their Phase 2 trial of XTX101 and preliminary data on XTX301, demonstrating their potential in treating solid tumors.
When will the ASCO GI presentation occur?
The presentation on XTX101 is scheduled for January 25, 2025, at the ASCO Gastrointestinal Symposium.
How does XTX301 work?
XTX301 is designed to stimulate anti-tumor immunity and transform the tumor microenvironment to enhance the treatment of cold tumors.
What future prospects exist for Xilio Therapeutics?
Xilio aims to continue developing its tumor-activated therapies to provide improved treatment options for cancer patients and to leverage partnerships with organizations like Gilead and Roche.
